UNSPSC 51351510: Megestrol

This classification denotes a therapeutic progestin with the molecular formula C22H30O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EA6LD1M70M, chemically known as 17-hydroxy-6-methylpregna-4,6-diene-3,20-dione but generally known as megestrol, which bears US NIH Compound Identifier 19090. European Medicines Agency schedules Megestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08712MIG. World Health Organization schedules megestrol in its Anatomical Therapeutic Chemical (ATC) Classification.

UNSPSC 51351510 Megestrol is a Commodity code encompassing pharmaceutical products supplied through state and local cooperative purchasing agreements. State and local governments procure megestrol and related generic multi-source pharmaceuticals through established wholesaler networks for distribution across health agencies, correctional facilities, and other public health institutions. The primary issuing bodies are state departments of health and administration, often acting through multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions and participating members. These procurements require vendors to hold current Good Manufacturing Practices certification and Drug Supply Chain Security Act compliance, maintain relationships with authorized pharmaceutical wholesalers, and meet stringent insurance, FDA approval, and product-shelf-life requirements.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products with a response deadline of March 26, 2026. The RFP covers generic pharmaceuticals including megestrol distributed through three authorized wholesalers—AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson—with awarded contracts effective July 1, 2026 and extending two years for new vendors. Evaluation is weighted heavily toward price competitiveness (75 percent) with secondary weight on fixed pricing, EDI capability, administrative fee compliance, and administrative data format compliance. Vendors must maintain $5 million in commercial general liability coverage and agree to a 3 percent administrative fee on all contract purchases. The RFP does not disclose specific award values or budget ranges.